Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma
International Journal of Molecular Sciences · 13.07.2026 · 27 (14) · 6228
DOI: 10.3390/ijms27146228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.07.2026. Verfasst von Huimin Qi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Immunotherapy, Bile Duct Neoplasms. Die Arbeit nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal and heterogeneous primary liver malignancy with a dismal prognosis. Approximately 70% of patients are diagnosed at locally advanced or metastatic stages, therefore missing the opportunity for curative surgery, and conventional chemotherapy offers limited survival benefits. Immunotherapy, especially immune checkpoint blockade, represents a promising strategy, yet its efficacy as monotherapy in iCCA remains modest primarily due to the profoundly immunosuppressive and desmoplastic tumor microenvironment. This review examines the immune cell infiltration landscape of iCCA, focusing on the distinct roles of lymphoid cells and myeloid cells in shaping immune evasion. We then analyze key factors affecting immune responses, such as tumor-intrinsic driver mutations, immune regulatory mechanisms, and acquired resistance. Furthermore, we summarize current clinical advances in iCCA immunotherapy, including immune checkpoint inhibitor monotherapy, bispecific antibodies, combination strategies with chemotherapy or targeted therapy, cancer vaccines, and adoptive cell therapy. Despite some progress, the overall response to immunotherapy remains suboptimal, and future strategies need to focus on deciphering context-specific resistance mechanisms and enhancing the tumor-specific immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Collaborative Research Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
- Shanghai Key Laboratory of Molecular Imaging and Digital and Intelligent Empowerment Biomedical Innovation Center, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
ORCID-Profile: Hailong Wu
Zitieren
APA
Qi, H., Pan, J., & Wu, H. (2026). Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences, 27(14), 6228. https://doi.org/10.3390/ijms27146228
Vancouver
Qi H, Pan J, Wu H. Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences. 2026;27(14):6228. doi:10.3390/ijms27146228
BibTeX
@article{Qi2026,
author = {Qi, Huimin and Pan, Jialin and Wu, Hailong},
title = {Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6228},
doi = {10.3390/ijms27146228}
}
EUVIMED